Navigation Links
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
Date:3/15/2013

ong-term complications related to either the surgery or the cells.
  • In July, Neuralstem received a notice of issuance for patent application number 12/710,097 (subsequently issued patent number 8,236,299) titled: "Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions." This patent, which will expire in the first quarter of 2030, covers both the culturing of central nervous system (CNS) cells as well as their transplantation into spinal cord tissue to treat neurodegenerative conditions, including ALS, ischemic stroke, and chronic and acute spinal cord injury.
  • Also in July, the company extended the employment contracts of Dr. Karl Johe , Richard Garr , and Dr. Thomas Hazel for an additional 60 months.
  • In September, Neuralstem received approval to commence a combined Phase I/II clinical trial to treat motor deficits due to ischemic stroke with direct injections into the brain of NSI-566 cells, at BaYi Brain Hospital, in Beijing, through its subsidiary, Neuralstem China (Suzhou Neuralstem Biopharmaceutical Company, Ltd.). The trial is designed to enroll up to 118 patients, and involve one-time intracerebral injections into the stroke area using well-accepted stereotactic injection procedures. Phase I will determine the maximum safe dose and the multi-site, randomized, controlled, single-blind Phase II/proof-of-concept study will evaluate efficacy, with 50 percent of the subjects receiving NSI-566 injections and physical therapy, and the other 50 percent receiving only the physical therapy. The combined trial, including patient monitoring and data collection, is expected to start in the first quarter and conclude in approximately two years following commencement.
  • Also in September, "Long-Distance Growth and Connectivity of Neural Stem Cells After Severe Spinal Cord Injury: C
    '/>"/>

  • SOURCE Neuralstem, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
    2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
    3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
    4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
    5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
    6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
    7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
    8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
    9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
    10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
    (Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
    (Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
    (Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
    Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
    ... , June 21 /PRNewswire-FirstCall/ - Aeterna Zentaris ... a late-stage drug development company specialized in oncology and ... announced registered direct offering of US$12.1 million ... purchase warrants to certain institutional investors. Net proceeds from ...
    ... June 21, 2010 The Pharmaceutical practice,at MarketsandMarkets is pleased to announce a new report ... , ... , , ... , , ...
    ... in power capacity as a result of a new finding ... for one of the battery,s electrodes produced a significant increase ... it could deliver from a given weight of material, compared ... in small portable devices, and with further research might also ...
    Cached Biology Technology:Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 2Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 2Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 4Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 2Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 3
    (Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
    (Date:7/9/2014)... southern Europe are less fit in terms of ... European peers. Moreover, southern adolescents are more obese ... fat than those from the centre-north of Europe. ... from an ambitious study conducted by scientists from ... in collaboration with 25 other European research groups. ...
    (Date:7/9/2014)... yield big savings, if they are used in ... the Brigham and Women,s Hospital and coauthors analyzed ... savingshigh-cost patients; readmissions; triage; decompensation (when a patient,s ... a disease affects multiple organ systems. They suspect ... current costs associated with all six scenarios will ...
    Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Adolescents from southern Europe are less fit and more obese than central-northern European peers 2The impact of big data on health care: Health Affairs' July issue 2
    ... CITY, MO Cells trying to keep pace with constantly ... between maintaining their genomic integrity and allowing enough genetic ... study, researchers at the Stowers Institute for Medical Research ... genomes become unstable, readily acquiring or losing whole chromosomes ...
    ... the genetic variance of human metabolism, researchers have identified ... with levels of circulating metabolites, i.e., small molecules that ... Many of the studied metabolites are biomarkers for cardiovascular ... provide valuable insight into the biological processes leading to ...
    ... the researchers to see an aspect of light that humans ... sensitive to polarized light, many reef dwelling animals are but ... studies of reef communities. Thanks to generous support provided ... team of researchers from the Ecology of Vision Laboratory in ...
    Cached Biology News:That which does not kill yeast makes it stronger 2That which does not kill yeast makes it stronger 3Genetic regulation of metabolomic biomarkers - paths to cardiovascular diseases and type 2 diabetes 2Capturing an octopus-eye view of the Great Barrier Reef 2
    ... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 50 minigels. A 1 mL unit size ...
    Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
    ... RSH-4000 is the only microplate sealer with ... long walkaway times with a variety of ... Fully automated with integrated stacker and 240-plate ... EX for use in small workcells , ...
    ... Reagents for the differentiation of mouse embryonic ... bodies exist in the midbrain, where they ... the ventral tegmental area, and the retrorubral ... to extensive forebrain dopamine innervation ( e.g.projections ...
    Biology Products: